Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
NCT ID NCT07722754
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wild-type, microsatellite-stable tumors that have spread and cannot be surgically removed. The main question is whether the four-drug mix leads to more tumor shrinkage than the two-drug standard.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of bevacizumab and sintilimab added to irinotecan and cetuximab
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a mid-stage trial with only 160 participants, so results may not apply broadly. Adding more drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
- Experimental drug SHR-A1904 takes on Hard-to-Treat colorectal cancer